Ankündigung • Apr 30

Bausch + Lomb Corporation Features More Than 40 Scientific Studies At The Association For Research In Vision And Ophthalmology Annual Meeting

Bausch + Lomb Corporation announced that it will deliver more than 40 scientific data presentations at the Association for Research in Vision and Ophthalmology Annual Meeting taking place in Denver, CO, May 3-7, 2026. Scientific posters and papers will highlight the results of various studies across the company’s broad portfolio of products including LUMIFY redness reliever eye drops, Blink NutriTears nutritional supplement, XIIDRA (lifitegrast ophthalmic solution) 5%, MIEBO (perfluorohexyloctane ophthalmic solution), INFUSE/ULTRA ONE DAY daily disposable contact lenses, Biotrue ONEday daily disposable contact lenses, enVista Envy Full Visual Range intraocular lenses (IOLs) and Stellaris Elite Vision Enhancement System. New data will also be presented on pipeline assets including the enVista Beyond extended depth of focus lens and investigational candidates in glaucoma, neuropathic pain, age-related macular degeneration (AMD) and lens care. Paper Presentations: “Effect of Physician Recommendation of AREDS2 Supplements on Structural Biomarkers of AMD Progression.” D. Chen et al. “The Effect of BL1107 on Intraocular Pressure and Visual Function in a Phase 2 Randomized Clinical Trial in Patients With Glaucoma or Ocular Hypertension.” S. Whitcup et al. “Disinfection Efficacy of a New Dual-Disinfectant Investigational Multi-Purpose Solution and Comparator Multi-Purpose Solutions Against Acanthamoeba Trophozoites.” W. Domm et al. Poster Presentations: “Examination of the Effects of Hyaluronic Acid on Cellular Metabolic Activity in Transformed Human Conjunctival and Corneal Epithelial Cells Exposed to Desiccation Stress” K. VanDerMeid et al. “Examination of the Effects of Glycerin on Cellular Metabolic Activity in Transformed Human Conjunctival and Corneal Epithelial Cells Exposed to Desiccation Stress.” J. Russell et al. “Patient-Reported Outcomes of a Supplement in Adults With Dry Eye Disease: A 56-Day In-Home Usage Study.” J. Poteet et al. “Global Unmet Needs in Dry Eye: A Comparative Assessment Across the United States and Five International Populations.” R. Ryan et al. “A Phase 3 Randomized Trial of a Novel Brimonidine Tartrate Ophthalmic Solution With Sodium Hyaluronate.” S. Kannarr et al. “Comparative Analysis of AREDS2 and AREDS2+B Vitamin Complex in an in vitro Model of Age-Related Macular Degeneration.” R. Srinivasagan et al. “Clinical Outcomes and Patient Experience Following IOL Exchange With a Full Visual Range Intraocular Lens.” R. Wong et al. “Outcomes of a Novel Full Visual Range Intraocular Lens in Eyes With Previous Corneal Refractive Surgery.” J. Wong et al. “Visual Outcomes at Different Distances With a Full Visual Range Intraocular Lens, a Case Series Study.” G. Lau et al. “Halo Characterization of Two Extended Range of Vision Intraocular Lenses.” J. Antonio Azor Morón et al. “Optical Evaluation of Halos in Multifocal Intraocular Lenses.” L.Nijm et al. “Optical Quality of Two Refractive Full Range of Vision Intraocular Lenses: Impact of Tilt and Decentration.” F. Vega et al. “Intermediate Vision Outcomes of Monofocal Intraocular Lenses Following Cataract Extraction: A Retrospective Cohort Study.” Schavee P et al. “Impact of IOL Asphericity on Simulated Defocus Curves.” F. Alba-Bueno et al. “Corneal Incision Temperature During Phaco Energy Activation - An ex vivo Comparative Study.” A. Papour et al. “Impact of Flow Rate and Ultrasound Energy on Viscoelastic Erosion in a Model Eye.” G. Higgins et al. “Early Outcomes of Standalone Excimer Laser Trabeculostomy in Open Angle Glaucoma: A Prospective Washout Study.” Patel B et al. “Real-World Characteristics of Autoimmune Patients With Dry Eye Disease Treated With Lifitegrast: Insights From the AAO IRIS Registry.” C. Koetting et al. “Physician Perspectives on the Clinical Use of Concomitant Perfluorohexyloctane and Lifitegrast in Dry Eye Disease Management: Results From a Nationwide Survey.” F. Mah et al. “BL1312 Significantly Reduces Pain Over 24 Hours Following Photorefractive Keratectomy: A Sum of Pain Intensity Differences Analysis.” L. Rajagopalan et al. “Risk Factors for Contralateral Eye Involvement in Non-Arteritic Anterior Ischemic Optic Neuropathy: A Retrospective Cohort Analysis of Electronic Health Records.” E. Donovan et al. “BL1332, a TRPV1 Antagonist, Reduces Capsaicin-Induced Acute Ocular Pain in a Rat Model.” V Vozella et al. “The Effects of BL1332, a novel TRPV1 Antagonist, on Corneal Wound Healing Rate and Corneal Sensitivity.” L. Christie et al. “A Novel Alpha2-Adrenergic Receptor Agonist, BL1106, has Structural and Functional Benefits in a Blue Light Model of Retinal Degeneration.” C. Harrower et al. “Retinal Bioavailability and Functional Effects of a Deuterium Labelled Very-Long-Chain Polyunsaturated Fatty Acid (VLC-PUFA) in Wild-Type and Transgenic Mice.” J. Bound David et al. “Early Response to Treatment With Lifitegrast Ophthalmic Solution in Patients With Dry Eye Disease: A Post Hoc Analysis of Two Randomized Trials.” J. Sheppard “Preoperative and Postoperative Treatment With Perfluorohexyloctane Ophthalmic Solution in Patients Undergoing Cataract Surgery: Effects on Signs and Symptoms of Dry Eye Disease.” E. Liang “Effects of Preoperative Treatment With Perfluorohexyloctane Ophthalmic Solution on Refractive Outcomes in Patients With Dry Eye Disease Undergoing Cataract Surgery.” J. Bacharach “Retrospective Real-World Evidence Study of Clinical Outcomes and Eyecare Practitioner Satisfaction With Topical Latanoprostene Bunod in Patients With Ocular Open-Angle Glaucoma or Ocular Hypertension.” N. Cothran et al. “Durability of Suprachoroidal Triamcinolone Acetonide in Eyes With Chronic Cystoid Macular Edema in Real-World Clinical Practice.” A. Talwar et al. “Suprachoroidal Triamcinolone Acetonide for Macular Edema: Real World Safety and Efficacy Outcomes From a Tertiary Eye Center.” A. Mobasserian et al. “Disinfection Efficacy of Acanthamoeba Trophozoites by Rigid Gas Permeable Contact Lens Care Products.” H. Wheeler et al. “Clinical Evaluation of a New Multi-Purpose Solution for Soft Contact Lens Wearers.” G Wesley et al. “Regimen Evaluation of a Biotrue Hydration Plus Multi-Purpose Solution Against ISO Microbial Organisms.” T. Bassage “Real-World Assessment of a Multi-Purpose Contact Lens Solution in Contact Lens Wearers With Heavy Digital Device Use and Contact Lens-Related Dryness.” J. Tsai et al. “A Meta-Analysis of the Safety of Nesofilcon a Soft Daily Disposable Hydrogel Contact Lenses.” K. Hoffman et al. “Real-World Evaluation of Patient Satisfaction and Experience With a Novel Daily Disposable Toric Contact Lens.” K. Bhagat et al. “New Contact Lens Wearers’ Real-World Experience and Satisfaction With a Novel Daily Disposable Toric Contact Lens.” J. Womack et al. XIIDRA Indications and Important Safety Information Indication Xiidra (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Ankündigung • Apr 07

Bausch + Lomb Corporation Announces New Scientific Data and Educational Events At the American Society of Cataract and Refractive Surgery Annual Meeting

Bausch + Lomb Corporation announced the presentation of new scientific data and events taking place during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., April 10-13, 2026. Forty-five presentations and posters will highlight the results of studies evaluating the company’s broad portfolio of products, including the ELIOS minimally-invasive glaucoma surgery (MIGS) system*, enVista Envy Full Visual Range and enVista Aspire intraocular lenses (IOLs), MIEBO (perfluorohexyloctane ophthalmic solution), ScoutPro point-of-care osmolarity testing device, Stellaris Elite Vision Enhancement System, TENEO Excimer Laser Platform and XIIDRA (lifitegrast ophthalmic solution) 5%. enVista Envy toric and non-toric IOL Indications: The enVista Envy hydrophobic acrylic IOL is indicated for primary implantation in the capsular bag of the eye in adult patients for visual correction of aphakia with less than or equal to 1.0 D preoperative corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL. The enVista Envy toric hydrophobic acrylic IOL is indicated for primary implantation in the capsular bag of the eye in adult patients for visual correction of aphakia and corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL. enVista Aspire hydrophobic acrylic IOL Indications: The enVista Aspire hydrophobic acrylic IOL (non-preloaded model EA) is indicated for primary implantation in the capsular bag of the eye in adult patients for the visual correction of aphakia following removal of a cataractous lens. The Aspire IOL uses an optical modification of the posterior aspheric surface to create a small continuous increase in IOL power within the central 1.5 mm diameter to slightly extend the depth of focus. However, clinically meaningful extension of the depth of focus has not been demonstrated in clinical trials. Potential complications accompanying cataract or implant surgery may include, but are not limited to the following: corneal endothelial damage, infection (endophthalmitis), retinal detachment, vitritis, cystoid macular edema, corneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon transient or persistent glaucoma, and secondary surgical intervention. Secondary surgical interventions include but are not limited to: lens repositioning, lens replacement, vitreous aspiration or iridectomy for pupillary block, wound leak repair, and retinal detachment repair. MIEBO Indications: MIEBO (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease. MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane. MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO. Instruct patients to instill one drop of MIEBO into each eye four times daily. The safety and efficacy in pediatric patients below the age of 18 have not been established. In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness. The ScoutPro Osmolarity System is an automated device intended to quantitatively measure the osmolarity of human tears to aid in the diagnosis of dry eye disease, in patients suspected of having dry eye disease in conjunction with other methods of clinical evaluation. Do not collect tear fluid from a patient within two hours of medicinal eye drop use or use of topical medications. Do not collect or store tear fluid samples for transport or testing at a later time. Do not collect tear fluid after ocular surface staining. Do not collect tear fluid within 15 minutes of use of anesthetic or mydriatic (dilating) eye drops or after other invasive ocular diagnostic testing. Do not collect tear fluid within 15 minutes after a slit lamp examination. Do not collect tear fluid within 15 minutes from a patient who has been crying. Stellaris Elite and Accessories Important Safety Information: The Bausch + Lomb Stellaris Elite vision enhancement system is intended for the emulsification and removal of cataracts, anterior and posterior segment vitrectomy. The system is designed for use in both anterior and posterior segment surgeries. It provides capabilities for phacoemulsification, coaxial and bimanual irrigation/aspiration, bipolar coagulation, vitrectomy, viscous fluid injection/removal and air/fluid exchange operations. The Stellaris Elite Vision Enhancement System configured with the laser module is additionally intended for retinal photocoagulation and laser trabeculoplasty. Use of accessories not designated by Bausch + Lomb for use with this equipment may result in serious permanent patient injury, adverse surgical outcome, or damage to the equipment. Photocoagulation is not indicated for patients without pigmentation (albino eyes). In addition, Laser Indirect Ophthalmoscope (LIO) is not indicated for cases involving laser photocoagulation within the arcades. Technolas Teneo 317 Model 2 System: The Technolas Teneo 317 Model 2 is indicated for laser-assisted in situ keratomileusis (LASIK) in: (1) Patients for the reduction or elimination of myopic astigmatism up to -10.00 D MRSE, with sphere between -1.00 D to -10.00 D and cylinder between 0.00 and -3.00 D; (2) Patients who are 22 years of age or older; (3) Patients must have a stable refraction in the last 12 months, as documented by previous clinical recordings, i.e., the spherical and cylindrical portions of the manifest distance refraction have not progressed at a rate of more than 0.50 D per year prior to the baseline examination in the eye(s) to be treated.

Medical Equipment Gewinnwachstum	16.6%
Wachstumsrate der Einnahmen	5.5%
Zukünftige Eigenkapitalrendite	7.15%
Analystenabdeckung	Good
Zuletzt aktualisiert	14 Jul 2026

Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	6,100	287	549	841	9
12/31/2027	5,780	143	391	661	13
12/31/2026	5,468	-55	232	738	13
3/31/2026	5,208	-219	1	340	N/A
12/31/2025	5,101	-360	-66	283	N/A
9/30/2025	4,976	-305	-196	169	N/A
6/30/2025	4,891	-273	-165	186	N/A
3/31/2025	4,829	-362	-168	166	N/A
12/31/2024	4,791	-317	-59	232	N/A
9/30/2024	4,684	-368	-58	225	N/A
6/30/2024	4,495	-456	-137	119	N/A
3/31/2024	4,314	-337	-131	80	N/A
12/31/2023	4,146	-260	-198	-17	N/A
9/30/2023	3,969	-207	-20	127	N/A
6/30/2023	3,904	-141	-57	106	N/A
3/31/2023	3,810	-104	116	286	N/A
12/31/2022	3,768	6	170	345	N/A
9/30/2022	3,773	58	144	348	N/A
6/30/2022	3,780	136	398	594	N/A
3/31/2022	3,773	175	482	688	N/A
12/31/2021	3,765	182	680	873	N/A
9/30/2021	3,708	-78	636	845	N/A
6/30/2021	3,675	-53	539	776	N/A
3/31/2021	3,517	-44	370	618	N/A
12/31/2020	3,412	-18	263	522	N/A
12/31/2019	3,778	298	N/A	799	N/A
12/31/2018	3,665	710	N/A	763	N/A

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/07/15 03:31
Aktienkurs zum Tagesende	2026/07/15 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

Analyst	Einrichtung
Travis Steed	BofA Global Research
Joanne Wuensch	Citigroup Inc
Philip Chickering	Deutsche Bank

Bausch + Lomb Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Bausch + Lomb Corporation Revises Earnings Guidance for the Year 2026

Bausch + Lomb Corporation Provides Earnings Guidance for the Full Year 2026

Price target increased by 7.4% to US$16.43

Consensus EPS estimates fall by 12%

Bausch + Lomb Corporation Provides Updated Guidance for the Full Year 2025

Bausch + Lomb Corporation Updates Earnings Guidance for the Full Year of 2025

Recent updates

Bausch + Lomb Ends Glaucoma Eye Drop Trial Plans Implant Study for Geographic Atrophy

BLCO: Fair View Balances Medtech Strength With Pipeline And Execution Risks

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate

Bausch + Lomb Introduces Orphia, an Ai-Powered Digital Health Platform

Bausch + Lomb Corporation to Report Q2, 2026 Results on Jul 29, 2026

BLCO: Product Pipeline And Higher 2026 Revenue Outlook Will Support Upside

Bausch + Lomb Stock Gains Exposure to New Corneal Disease Treatment With Emmecell Investment

Bausch + Lomb Launches Blink Triple Care Preservative Free Lubricant Eye Drops in the United States

Bausch + Lomb: Even Though Growth Continues, I Don't See A Way Higher

Bausch + Lomb Expands Eye Health With AREDS3 Launch and Strong Growth in Dry Eye Portfolio

Bausch + Lomb Corporation Launches PreserVision AREDS3 Eye Vitamins In The United States

Executive VP & CFO exercised options to buy US$988k worth of stock.

Bausch + Lomb Corporation Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe

Bausch + Lomb Corporation Revises Earnings Guidance for the Year 2026

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation Features More Than 40 Scientific Studies At The Association For Research In Vision And Ophthalmology Annual Meeting

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

$BLCO $BHC $COO file their ARS annual financial reports and Proxy statements stating divestiture of Lens Care Vision units but no announcem

$BLCO $BHC $COO BHC’s ARS clearly states the divestment and discontinuation of the Vision Care Business! When will the finally announce!

$Cooper $Bausch + Lomb Corporation DEAL‑CERTAINTY SCORECARD (Final, Fully Integrated Version from AI and my opinion Score: 100/100 — Maxi

Bausch + Lomb Corporation Receives FDA 510(k) Clearance For Bi-Blade+ Dual-Port Vitrectomy Cutter And Adaptive Fluidics Advanced Update

Bausch + Lomb Corporation Announces New Scientific Data and Educational Events At the American Society of Cataract and Refractive Surgery Annual Meeting

$BLCO & $COO The Silence BEFORE the AGM: A Retail Investor’s Timeline, Findings, and Opinion on SUSPICIOUS SILENCE!

Bausch + Lomb Corporation to Report Q1, 2026 Results on Apr 29, 2026

Bausch + Lomb Corporation Announces Positive 24-Month U.S. Data on the Elios System for Treatment of Glaucoma

CEO & Chairman exercised options to buy US$10m worth of stock.

Bausch + Lomb Corporation, Annual General Meeting, May 20, 2026

CEO & Chairman exercised options and sold US$1.2m worth of stock

Bausch + Lomb Corporation Announces That Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY

Full year 2025 earnings: EPS misses analyst expectations

Bausch + Lomb Corporation Provides Earnings Guidance for the Full Year 2026

Bausch + Lomb Corporation to Report Q4, 2025 Results on Feb 18, 2026

Bausch + Lomb Corporation Announces Board Appointments, Effective January 1, 2026

Price target increased by 7.4% to US$16.43

Consensus EPS estimates fall by 12%

Third quarter 2025 earnings: EPS misses analyst expectations

Bausch + Lomb Corporation Provides Updated Guidance for the Full Year 2025

Bausch + Lomb Corporation to Report Q3, 2025 Results on Oct 29, 2025

Bausch + Lomb Announces Publication of enVista Envy™? Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Bausch + Lomb Announces Publication of Data from A Prospective Study Evaluating the Efficacy of XIIDRA®? in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Bausch + Lomb Corporation Launches ASANA Gas Permeable Lenses in the United States

Bausch + Lomb Announces Board Changes

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Bausch + Lomb Corporation Updates Earnings Guidance for the Full Year of 2025

Bausch + Lomb Corporation Announces Publication of Phase 3 Data on Lumify®? Preservative Free Redness Reliever Eye Drops

Bausch + Lomb Corporation Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions About Dry Eye

Bausch + Lomb Corporation to Report Q2, 2025 Results on Jul 30, 2025

Bausch + Lomb Launches Blink Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

Bausch + Lomb Launches New LUMIFY Preservative Free Redness Reliever Eye Drops in the United States

Bausch + Lomb Corporation Launches Zenlens Chroma Hoa in the United States

Consensus EPS estimates fall by 298%

Bausch + Lomb Corporation Receives European Ce Mark Approval for Preloaded Luxlife Full Range of Vision Intraocular Lens

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2025

Bausch + Lomb Corporation Announces enVista Intraocular Lenses to Market Following Voluntary Recall

Price target decreased by 8.7% to US$18.86

Bausch + Lomb Corporation to Report Q1, 2025 Results on Apr 30, 2025

Bausch + Lomb Corporation, Annual General Meeting, May 21, 2025

Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room

Full year 2024 earnings: EPS misses analyst expectations

Bausch + Lomb Provides Update on Potential Sale

Bausch + Lomb Corporation to Report Q4, 2024 Results on Feb 19, 2025

Bausch + Lomb Corporation Launches enVista Aspire Intermediate Optimized Monofocal and Toric Intraocular Lenses in European Union

Bausch + Lomb Corporation (NYSE:BLCO) acquired Whitecap Biosciences LLC.

Bausch + Lomb Responds to Rumors of a Potential Sale

Bausch + Lomb Corporation (NYSE:BLCO) acquired ELIOS Vision, Inc.

Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News

Bausch + Lomb Corporation Revises Earnings Guidance for the Full Year of 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations